Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Rectal Neoplasms 3Colorectal Neoplasms 3Colonic Neoplasms 3Lung Neoplasms 2Esophageal Neoplasms 2Breast Neoplasms 2Wilms Tumor 1Waldenstrom Macroglobulinemia 1Urinary Bladder Neoplasms 1Stomach Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Small Cell Lung Carcinoma 1Prostatic Neoplasms 1Ovarian Neoplasms 1Neoplasms 1Lymphoma, Mantle-Cell 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, Follicular 1Leukemia, Lymphocytic, Chronic, B-Cell 1Leukemia 1Kidney Neoplasms 1Head and Neck Neoplasms 1Esthesioneuroblastoma, Olfactory 1Esophageal Squamous Cell Carcinoma 1Carcinoma, Renal Cell 1Carcinoma, Ovarian Epithelial 1Carcinoma, Non-Small-Cell Lung 1Bronchiolitis Obliterans Syndrome 1Breast Neoplasms, Male 1Adenocarcinoma Of Esophagus 1

Interventions

Paclitaxel 10Radiotherapy 7Fluorouracil 7pembrolizumab 6Carboplatin 6Oxaliplatin 5Cisplatin 5lenvatinib 3Neoadjuvant Therapy 3Cetuximab 3tislelizumab 2camrelizumab 2Surgical Procedures, Operative 2Nivolumab 2Leucovorin 2Irinotecan 2Drug Therapy 2Docetaxel 2tremelimumab 1toripalimab 1regorafenib 1osimertinib 1oblimersen 1nimotuzumab 1nedaplatin 1monalizumab 1enzalutamide 1durvalumab 1aflibercept 1abiraterone 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Esophageal Squamous Cell Carcinoma × oblimersen × Clear all
NCT00064259 2021-02-17

A Phase I/II Study of Oblimersen Plus Cisplatin and Fluorouracil in Gastric & Esophageal Junction Cancer

National Cancer Institute (NCI)

Phase 1/2 Terminated
15 enrolled 5 charts
Gastrointestinal

Adenocarcinoma Of Esophagus, Esophageal Squamous Cell Carcinoma, Esophageal Neoplasms, Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡